New York Stem Cell Summit 2012
Reflecting the dynamic nature of the industry, this year’s Stem Cell Summit has a record number of new presenters and one notable drop out—Geron. No question, adult stem cells are king of the hill for clinicians, but are embryonic stem cell therapies gone for good? The answer may surprise. Read on.
Inherit the Wind starring Spencer Tracy, Frederick March and Harry Morgan. Courtesy Wikimedia Commons
In the recent issue of The Spine Journal, Eugene Carragee, M.D., writes more like prosecutor-in-chief than editor-in-chief as he resumes his attack on the use of rhBMP2 and its clinical investigators. The plaintiff’s bar is cheering. But NASS members are reeling. Who to believe? Read the details here.
Image created by RRY Publications, LLC. Source: MiMedx
Question: What are three terrific new technologies or companies in orthopedics? We see new product ideas and companies every week, but these three recent candidates stood out for their innovation and practicality. See if you agree.
Image creation by RRY Publications, LLC. Source: Wikimedia Commons
Five companies, we think, stand out when it comes to non-allograft stem cells. These firms either have stem cell products on the market or are in the very advanced stages of bringing therapeutic stem cells to the rank and file orthopedic surgeon. Check it out.
Source: Wikimedia Commons and Alejandro zorrilal Cruz
Ten potentially disruptive trends are gathering momentum. Some or all of these, we think, will change orthopedics forever. From least to most, here are our picks for the coming disruptive trends in products, services, hospitals and employment in orthopedics.
Photo manipulation by RRY Publications. Source: Wikimedia and Jack Gilmour
This week, in Part II of our review of The Spine Journal’s BMP issue, we tackle some of the other issues raised by the Journal, notably corporate funding of the InFuse studies. Then we look at the broader implications of the Journal’s review on innovation and self-regulation in the spine surgery community.
Source: RRY Publications
First The Spine Journal devotes its entire June 29th issue to repudiating studies—one of which once appeared in its own pages. Then a Wall Street analyst speculated that Medtronic might divest itself of InFuse or Spine or both. Surgeons are upset. It’s a mess. Using PearlDiver data we try to sort fact from fiction.
1 Comment